NEW YORK (GenomeWeb News) – Newly minted public company Cancer Genetics has disclosed that it will invest at least $2.0 million, and potentially up to $6.0 million, into a joint venture the firm formed in November 2011 with the Mayo Foundation for Medical Education and Research.

The Rutherford, NJ-based cancer molecular diagnostics company disclosed more details about the joint venture in its Form 10-Q, filed this week with the US Securities and Exchange Commission. The JV is focused on the development of oncology diagnostics based on next-generation sequencing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.